Empowered Patient Podcast Reducing the Time Burden of Infusions with Subcutaneous Delivery of Biologics by Patients with Jeff Hackman Comera Life Sciences
Jeff Hackman, CEO of Comera Life Sciences, recognizes the need to find a more efficient, patient-friendly solution for receiving biologics rather than being administered by IV therapy. Using the SQore platform, a proprietary technology, Comera is reformulating IV biologics to Sub-Q utilizing small molecule chemistry and an understanding of excipients. Seven out of ten global medicines are biologics, and most are administered by IV, providing a tremendous opportunity to expand access to biologics using Sub-Q technology.
Jeff elaborates, "Our mission is to transform these biologic therapies into a different form, a subcutaneous form. That form takes on the ability of these patients to administer these medicines for themselves, at home, at school, and at work. So really, what the summary of this mission is, through the freedom of self-injectable care, we hope that these patients can live a life without the burden of this therapy and the ability to be able to make their lives more livable."
"Excipients have been around for decades. They often fail to reduce the viscosity necessary to get these high-potency biologics into these small spaces, these small syringes, as you said. Our technology, which is called the SQore platform, allows this to happen more often, and it's such a significant impact that we have had multiple partnerships and collaborations with large pharma over the years to work with them to be able to do this."
"The issue you have around the science and the platform is that by taking and putting large molecules like this and these biologics into small spaces that are very potent, these biologics and antibodies stick together. So what our technology does is it's viscosity-reducing. That viscosity, you can think about it as when you put these biologics into a small syringe, they almost look like oil or glue."
"The ability to be able to stabilize these and to be able to get them to flow around each other and to be injected at these high potency levels is what our SQore platform does."
#ComeraLifeSciences #Biologics #IVInfusion #Subcutaneous #SubQ #Immunotherapy #SQore #Excipients